AirSculpt Technologies, Inc. (AIRS) AI Stock Analysis
AIRS AI stock analysis summary
AI ResearchAirSculpt Technologies, Inc. (AIRS) provides minimally invasive body contouring and fat transfer procedures across the United States. Revenue contracted 15.8% in FY2025 to $151.8M, resulting in a net loss of -$11.7M. Over the past year, the stock fell 86.6% to $1.27, bringing its market capitalization to $91.9M.
- Market cap
- $91.9M
- Revenue (TTM)
- $150.7M
- P/E
- —
- 1Y return
- -86.6% S&P 500 16.8%
- Avg. target
- $4.50 252.9% vs last close
Bull case
- Analysts maintain a mean price target of $4.50, which sits 252.9% above the last close of $1.27.
- For the next fiscal year, analyst estimates project revenue growth of 2.6% to $155.0M alongside an 83.3% improvement in EPS to -$0.01.
- The company's price-to-sales ratio of 0.6x trades below the median of 4.1x for its US-listed Healthcare peers.
Bear case
- Revenue fell 15.8% in FY2025 to $151.8M as the company generated a net loss of -$11.7M.
- The stock has dropped 86.6% over the trailing 12 months, trading close to its 52-week low of $1.24.
- The balance sheet carries $51.6M in net debt with a current ratio of 0.79 as of June 30, 2026.
What AirSculpt Technologies does
AirSculpt Technologies, Inc. operates as a holding company for EBS Intermediate Parent LLC, specializing in advanced body contouring procedures throughout the United States. Its proprietary AirSculpt technology provides a minimally invasive approach for customizable fat removal. The company also offers fat transfer services using a patient's own fat cells for areas such as breasts, buttocks, and hips. Its specialized treatment portfolio includes Power BBL, Up a Cup, and Hip Flip. As of March 10, 2022, the company operated 19 centers across 15 states. Founded in 2012, AirSculpt Technologies is headquartered in Miami Beach, Florida.
Growth and profitability
AirSculpt generated a 5-year revenue CAGR of 19.3% from FY2020 to FY2025, but annual revenue contracted from a peak of $195.9M in FY2023 to $180.3M in FY2024 and $151.8M in FY2025. Gross margin decreased from 66.6% in FY2021 to 59.4% in FY2025, while operating margin shifted from 11.8% to -3.2%. Net income fell from $10.6M in FY2021 to -$11.7M in FY2025. Trailing twelve months revenue stands at $150.7M with an operating margin of -0.1% and diluted EPS of -$0.17. For the latest quarter ended June 30, 2026, revenue dropped 2.5% year-over-year, while quarterly earnings grew 200.0%.
Balance sheet and cash flow
As of June 30, 2026, AirSculpt held $18.8M in cash and short-term investments against total debt of $70.5M, leaving net debt at $51.6M. Total assets were $193.3M compared to shareholders' equity of $104.8M, yielding a debt-to-equity ratio of 0.67 and a current ratio of 0.79. During FY2025, operating cash flow was $3.1M and free cash flow reached $692,000, with capital expenditures totaling $2.4M. Its share count rose 27.9% over five years.
Valuation and performance
At $1.27 per share, AirSculpt carries an enterprise value of $207.4M and trades at a price-to-sales ratio of 0.6x, compared to 4.1x for the median of its US-listed Healthcare peers. Its EV-to-EBITDA multiple stands at 267.3x versus the peer median of 12.0x, while price-to-book is 1.5x. Over the past year, the stock fell 86.6%, trailing the S&P 500 return of 16.8%. Year-to-date, shares have declined 35.6% and trade 59.7% below their 200-day moving average.
What analysts expect
Wall Street analyst coverage consists of 1 Buy rating and 2 Hold ratings. The mean price target of $4.50 implies upside of 252.9% relative to the last close of $1.27. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.06 on revenue of $151.0M. For next fiscal year, analysts anticipate an EPS of -$0.01 on revenue of $155.0M. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 6, 2026.
Key risks and what to watch
- A current ratio of 0.79 indicates short-term obligations exceed current liquid assets.
- Total debt of $70.5M significantly exceeds cash and short-term investments of $18.8M as of June 30, 2026.
- A stock beta of 2.33 signals elevated price volatility amid a trailing twelve-month profit margin of -7.8%.
- The company has exceeded quarterly EPS expectations in only 1 of the last 4 quarters.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AIRS AI stock analysis
This page is an AI-written research summary of AirSculpt Technologies, Inc. (AIRS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AIRS income statement, AIRS balance sheet, AIRS key metrics, AIRS analyst forecast, AIRS chart. See the AIRS stock overview for the latest quote and news.
AIRS AI stock analysis FAQ
What was AirSculpt Technologies' revenue in FY2025?
AirSculpt reported annual revenue of $151.8M in FY2025, representing a 15.8% decline from $180.3M in FY2024.
Does AirSculpt Technologies pay a dividend?
AirSculpt Technologies does not pay a dividend.
What is the consensus analyst price target for AIRS?
The mean analyst price target is $4.50, representing upside of 252.9% from the October 16, 2026 closing price of $1.27.
How much debt does AirSculpt Technologies carry?
As of June 30, 2026, AirSculpt had total debt of $70.5M and cash and short-term investments of $18.8M, resulting in net debt of $51.6M and a debt-to-equity ratio of 0.67.